在治疗性结肠炎和多发性硬化症时,明智地使用ozanimod
Gabriela F Jhon1, Erin M Forster2
1Department of Internal Medicine, Grand Strand Medical Center, Myrtle Beach, SC.
ACG case reports journal
|April 17, 2024
概括
一种斯芬戈-1-酸盐受体调节剂Ozanimod有效地治疗了患有性结肠炎和多发性硬化症的患者. 这种药物为对其他治疗方法不耐受的患者提供了成功的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 性结肠炎和多发性硬化症是慢性炎症疾病.
- 奥萨尼莫德是一种口服的基-1-酸盐受体调节剂,已被批准用于性结肠炎.
- 患者对已建立的性结肠炎治疗方法的不耐受性会给治疗带来挑战.
研究的目的:
- 报告在患有中度至重度性结肠炎和多发性硬化症的患者中ozanimod的成功同时使用情况.
- 评估ozanimod在同时在两种条件下实现临床缓解的疗效.
主要方法:
- 一份病例报告,详细说明单个患者的治疗情况.
- 用于治疗性结肠炎和多发性硬化症的口服ozanimod的管理.
- 对这两种情况的临床缓解和疾病活性的监测.
主要成果:
- 患者在性结肠炎和多发性硬化症中实现了临床缓解.
- 奥扎尼莫德在治疗同时发生的炎症状况方面表现出有效性.
- 成功管理患者对多种先前治疗不耐受.
结论:
- 对于患有性结肠炎和多发性硬化症同时存在的患者来说,ozanimod可以是一个有益的治疗选择.
- 这一案例凸显了基-1-酸盐受体调节器在管理多种免疫媒介疾病方面的潜力.
- 需要进一步调查ozanimod的双重疗效.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Inflammatory Bowel Disease I: Ulcerative Colitis
173
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
173


